dc.contributor.author | Boussios, Stergios | en |
dc.contributor.author | Pentheroudakis, George | en |
dc.contributor.author | Katsanos, K. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Boussios, Stergios | en |
dc.creator | Pentheroudakis, George | en |
dc.creator | Katsanos, K. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:52:42Z | |
dc.date.available | 2018-06-22T09:52:42Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/41464 | |
dc.description.abstract | The toxicity of cancer chemotherapy is among the most important factors limiting its use. Clear delineation and communication of benefits and risks is an essential component of treatment decisions. Gastrointestinal toxicity during chemotherapy is frequent and contributes to dose reductions, delays and cessation of cancer treatment. The development of intervention strategies that could eliminate an expected side effect of chemotherapy is vital. Physiologic changes that can increase the toxicity of chemotherapy are decreased stem cell reserves, decreased ability to repair cell damage, progressive loss of body protein, and accumulation of body fat. Symptoms only arise when physiological functions are altered. The gastrointestinal symptoms arising during cancer chemotherapy can often be cured if newly acquired, and if gastrointestinal physiological deficits are identified. Developing new chemotherapy regimens with similar efficacy but less toxicity should be a priority for future research. © 2012 Hellenic Society of Gastroenterology. | en |
dc.language.iso | eng | en |
dc.source | Annals of Gastroenterology | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Cisplatin | en |
dc.subject | Cytarabine | en |
dc.subject | Dacarbazine | en |
dc.subject | Doxorubicin | en |
dc.subject | Fluorouracil | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Patient care | en |
dc.subject | Procarbazine | en |
dc.subject | Carboplatin | en |
dc.subject | Chemotherapy | en |
dc.subject | Abdominal pain | en |
dc.subject | Anorexia | en |
dc.subject | Bone marrow suppression | en |
dc.subject | Constipation | en |
dc.subject | Diarrhea | en |
dc.subject | Drug efficacy | en |
dc.subject | Mucosa inflammation | en |
dc.subject | Nausea and vomiting | en |
dc.subject | Ondansetron | en |
dc.subject | Oxaliplatin | en |
dc.subject | Stomatitis | en |
dc.subject | Taxane derivative | en |
dc.subject | Review | en |
dc.subject | Erlotinib | en |
dc.subject | Imatinib | en |
dc.subject | Unindexed drug | en |
dc.subject | Gastrointestinal symptom | en |
dc.subject | Incidence | en |
dc.subject | Neurologic disease | en |
dc.subject | Clinical feature | en |
dc.subject | Side effect | en |
dc.subject | Vomiting | en |
dc.subject | Colitis | en |
dc.subject | Loperamide | en |
dc.subject | Nausea | en |
dc.subject | Cancer | en |
dc.subject | Drug dose reduction | en |
dc.subject | Abdominal discomfort | en |
dc.subject | Acute hepatitis | en |
dc.subject | Alanine aminotransferase blood level | en |
dc.subject | Albumin blood level | en |
dc.subject | Alkaline phosphatase blood level | en |
dc.subject | Alkylating agent | en |
dc.subject | Aminotransferase blood level | en |
dc.subject | Amylase blood level | en |
dc.subject | Anthracycline derivative | en |
dc.subject | Anus disease | en |
dc.subject | Anus inflammation | en |
dc.subject | Ascites | en |
dc.subject | Aspartate aminotransferase blood level | en |
dc.subject | Bevacizumab | en |
dc.subject | Bilirubin blood level | en |
dc.subject | Body fat | en |
dc.subject | Bortezomib | en |
dc.subject | Cell damage | en |
dc.subject | Cell regeneration | en |
dc.subject | Cholestasis | en |
dc.subject | Colon ulcer | en |
dc.subject | Digestive system fistula | en |
dc.subject | Digestive system perforation | en |
dc.subject | Digestive system ulcer | en |
dc.subject | Drug research | en |
dc.subject | Drug withdrawal | en |
dc.subject | Dyspepsia | en |
dc.subject | Enteritis | en |
dc.subject | Esophagitis | en |
dc.subject | Esophagus ulcer | en |
dc.subject | Fluoropyrimidine derivative | en |
dc.subject | Gastritis | en |
dc.subject | Gastroesophageal reflux | en |
dc.subject | Gastrointestinal disease | en |
dc.subject | Gastrointestinal hemorrhage | en |
dc.subject | Gastrointestinal toxicity | en |
dc.subject | Gefitinib | en |
dc.subject | Gingivitis | en |
dc.subject | Glossodynia | en |
dc.subject | Granisetron | en |
dc.subject | Granulomatous hepatitis | en |
dc.subject | Hemoptysis | en |
dc.subject | Hemorrhagic colitis | en |
dc.subject | Hemorrhagic gastritis | en |
dc.subject | Hemorrhoid | en |
dc.subject | Hepatitis | en |
dc.subject | Hiccup | en |
dc.subject | Hyperbilirubinemia | en |
dc.subject | Ifosfamide | en |
dc.subject | Ileus | en |
dc.subject | Interpersonal communication | en |
dc.subject | Intestinal fibrosis | en |
dc.subject | Intestine necrosis | en |
dc.subject | Intestine ulcer | en |
dc.subject | Kidney dysfunction | en |
dc.subject | Lactate blood level | en |
dc.subject | Liver cirrhosis | en |
dc.subject | Liver disease | en |
dc.subject | Liver dysfunction | en |
dc.subject | Liver sinusoidal dilatation | en |
dc.subject | Liver vein thrombosis | en |
dc.subject | Medical decision making | en |
dc.subject | Melena | en |
dc.subject | Mouth inflammation | en |
dc.subject | Mouth ulcer | en |
dc.subject | Nitrosourea | en |
dc.subject | Octreotide | en |
dc.subject | Pancreatitis | en |
dc.subject | Paralytic ileus | en |
dc.subject | Pharyngitis | en |
dc.subject | Proctitis | en |
dc.subject | Protein depletion | en |
dc.subject | Rectum hemorrhage | en |
dc.subject | Risk benefit analysis | en |
dc.subject | Sorafenib | en |
dc.subject | Stomach ulcer | en |
dc.subject | Sunitinib | en |
dc.subject | Temsirolimus | en |
dc.subject | Tenesmus | en |
dc.subject | Therapy delay | en |
dc.subject | Tongue disease | en |
dc.subject | Tongue hyperpigmentation | en |
dc.subject | Triacylglycerol lipase blood level | en |
dc.subject | Tropisetron | en |
dc.subject | Xerostomia | en |
dc.title | Systemic treatment-induced gastrointestinal toxicity: Incidence, clinical presentation and management | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 25 | |
dc.description.issue | 2 | |
dc.description.startingpage | 106 | |
dc.description.endingpage | 118 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.contributor.orcid | Boussios, Stergios [0000-0002-2512-6131] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 | |
dc.gnosis.orcid | 0000-0002-2512-6131 | |